Provided by Tiger Fintech (Singapore) Pte. Ltd.

Celldex Therapeutics

21.21
-0.2300-1.07%
Post-market: 21.13-0.0800-0.38%18:28 EDT
Volume:841.05K
Turnover:17.73M
Market Cap:1.41B
PE:-7.86
High:21.66
Open:21.45
Low:20.73
Close:21.44
52wk High:47.00
52wk Low:14.40
Shares:66.39M
Float Shares:52.89M
Volume Ratio:0.98
T/O Rate:1.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.6987
EPS(LYR):-2.4515
ROE:-23.20%
ROA:-16.88%
PB:2.00
PE(LYR):-8.65

Loading ...

Celldex Therapeutics Q2 EPS $(0.85) Misses $(0.83) Estimate, Sales $730.000K Miss $1.007M Estimate

Benzinga
·
9 hours ago

Celldex Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
2 hours ago

TD Cowen Remains a Buy on Celldex (CLDX)

TIPRANKS
·
6 hours ago

Celldex Therapeutics Q2 Revenue USD 730 Thousand

THOMSON REUTERS
·
9 hours ago

Celldex Therapeutics Q2 EPS USD -0.85 VS. Ibes Estimate USD -0.86

THOMSON REUTERS
·
9 hours ago

Sumitomo Pharma and RACTHERA Submit Application for Regulatory Review of iPS Cell-Derived Treatment for Parkinson's Disease in Japan

Reuters
·
Yesterday

Sumitomo Pharma Co Ltd - Submission Of Application Of Manufacturing And Marketing Authorization For Ips Cell-Derived Dopaminergic Neural Progenitor Cells In Japan

Reuters
·
Aug 05

Celldex Therapeutics’ Phase 3 Study: A Potential Breakthrough for Chronic Urticaria

TIPRANKS
·
Jul 31

Sartorius Stedim Biotech Signs MoU With Sensible Biotechnologies On Cell-Based mRNA Production

Reuters
·
Jul 09

Celldex Therapeutics’ Promising Phase 2 Study on Eosinophilic Esophagitis

TIPRANKS
·
Jun 28

Exozymes Inc. Joins $9M NSF-Funded Meta-PURE Initiative to Revolutionize Cell-Free Biomanufacturing with Key Industry Partners

Reuters
·
Jun 27

Analysts Are Bullish on Top Healthcare Stocks: Schrodinger (SDGR), Celldex (CLDX)

TIPRANKS
·
Jun 17

Celldex Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 16

Celldex announces data on barzolvolimab from its Phase 2 trial in CSU

TIPRANKS
·
Jun 16

BRIEF-Celldex Presents Data Demonstrating Profound Long Term Improvement In Angioedema In Barzolvolimab Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci 2025

Reuters
·
Jun 14

Cantor Fitzgerald Remains a Buy on Celldex (CLDX)

TIPRANKS
·
Jun 13

Celldex Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 13

Celldex says Phase 2 Barzolvolimab study met primary endpoint

TIPRANKS
·
Jun 13

BRIEF-Celldex Presents Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci Congress 2025

Reuters
·
Jun 13

Celldex Therapeutics Files Initial Statement of Beneficial Ownership for Director Denice Torres

Reuters
·
Jun 06